The FDA and Baxter International are investigating three reports of adverse events, including two deaths, of patients at Beebe Medical Center in Delaware who were given the blood thinner heparin. Separate tests conducted by the agency and Baxter did not reveal signs of contamination, an FDA spokeswoman said.

Related Summaries